CYTOKINETICS, INCORPORATED (CYTK) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Win.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Win.
49/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 10 wins, 2 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinCYTK / S&P 29.25% / 15.20% |
LoseCYTK / S&P -21.07% / 15.00% |
LoseCYTK / S&P 41.57% / 50.40% |
| 2026-Q13/3 |
WinCYTK / S&P 3.73% / -4.33% |
WinCYTK / S&P 450.60% / 11.30% |
WinCYTK / S&P 29.30% / 27.70% |
| 2025-Q43/3 |
WinCYTK / S&P 15.61% / 2.65% |
WinCYTK / S&P 376.56% / 9.00% |
WinCYTK / S&P 24.14% / 13.40% |
| 2025-Q33/3 |
WinCYTK / S&P 66.34% / 8.12% |
WinCYTK / S&P 2609.26% / 4.61% |
WinCYTK / S&P 16.91% / 13.45% |
| 2025-Q21/3 |
LoseCYTK / S&P -17.79% / 10.94% |
WinCYTK / S&P 2635.74% / 4.83% |
LoseCYTK / S&P -5.03% / 10.63% |
| 2025-Q11/3 |
LoseCYTK / S&P -14.56% / -4.27% |
WinCYTK / S&P 412.21% / 4.98% |
LoseCYTK / S&P -2.04% / 10.57% |
| 2024-Q41/3 |
LoseCYTK / S&P -10.91% / 2.41% |
WinCYTK / S&P 145.34% / 5.25% |
LoseCYTK / S&P -3.49% / 6.15% |
| 2024-Q30/3 |
LoseCYTK / S&P -2.55% / 5.89% |
LoseCYTK / S&P -58.81% / 5.89% |
LoseCYTK / S&P -3.06% / 6.11% |
| 2024-Q20/3 |
LoseCYTK / S&P -22.72% / 4.28% |
LoseCYTK / S&P -68.51% / 5.38% |
LoseCYTK / S&P -6.12% / 5.12% |
| 2024-Q11/3 |
LoseCYTK / S&P -16.03% / 10.56% |
LoseCYTK / S&P -96.17% / 5.71% |
WinCYTK / S&P 17.14% / 5.59% |
| 2023-Q42/3 |
WinCYTK / S&P 183.40% / 11.69% |
LoseCYTK / S&P -92.04% / 6.81% |
WinCYTK / S&P 27.34% / 7.78% |
| 2023-Q31/3 |
LoseCYTK / S&P -9.69% / -3.27% |
LoseCYTK / S&P -94.73% / 7.52% |
WinCYTK / S&P 77.88% / -5.03% |
| 2023-Q21/3 |
LoseCYTK / S&P -7.30% / 8.74% |
LoseCYTK / S&P -93.42% / 9.50% |
WinCYTK / S&P 124.31% / -8.57% |
| 2023-Q12/3 |
LoseCYTK / S&P -23.20% / 7.50% |
WinCYTK / S&P 50.79% / 10.77% |
WinCYTK / S&P 44.97% / -15.69% |
| 2022-Q41/3 |
LoseCYTK / S&P -5.43% / 7.56% |
WinCYTK / S&P 34.30% / 11.88% |
LoseCYTK / S&P CYTK unavailable / -17.99% |
| 2022-Q32/3 |
WinCYTK / S&P 23.31% / -4.88% |
WinCYTK / S&P 587.85% / 13.47% |
LoseCYTK / S&P CYTK unavailable / -1.41% |
| 2022-Q22/3 |
WinCYTK / S&P 6.74% / -16.10% |
WinCYTK / S&P 161.51% / 13.71% |
LoseCYTK / S&P CYTK unavailable / 11.04% |
| 2022-Q10/3 |
LoseCYTK / S&P -19.24% / -4.60% |
LoseCYTK / S&P 11.06% / 15.97% |
LoseCYTK / S&P CYTK unavailable / 42.23% |
| 2021-Q42/3 |
WinCYTK / S&P 27.53% / 11.03% |
WinCYTK / S&P 26.15% / 15.00% |
LoseCYTK / S&P CYTK unavailable / 96.40% |
| 2021-Q31/3 |
WinCYTK / S&P 80.60% / 0.58% |
LoseCYTK / S&P -60.33% / 10.77% |
LoseCYTK / S&P CYTK unavailable / 69.42% |
| 2021-Q21/3 |
LoseCYTK / S&P -14.92% / 8.55% |
WinCYTK / S&P 209.34% / 6.58% |
LoseCYTK / S&P CYTK unavailable / 51.81% |
| 2021-Q12/3 |
WinCYTK / S&P 11.93% / 6.17% |
WinCYTK / S&P 163.40% / -1.06% |
LoseCYTK / S&P CYTK unavailable / 7.39% |
| 2020-Q41/3 |
LoseCYTK / S&P -4.02% / 12.15% |
WinCYTK / S&P 107.79% / -3.72% |
LoseCYTK / S&P CYTK unavailable / -33.42% |
| 2020-Q31/3 |
LoseCYTK / S&P -8.15% / 8.93% |
WinCYTK / S&P 75.03% / -2.04% |
LoseCYTK / S&P CYTK unavailable / -27.10% |
| 2020-Q21/3 |
WinCYTK / S&P 99.92% / 20.54% |
LoseCYTK / S&P -47.54% / -0.46% |
LoseCYTK / S&P CYTK unavailable / -27.11% |
| 2020-Q11/3 |
WinCYTK / S&P 11.12% / -19.60% |
LoseCYTK / S&P -35.93% / 3.47% |
LoseCYTK / S&P CYTK unavailable / -14.75% |
| 2019-Q40/3 |
LoseCYTK / S&P -6.77% / 9.07% |
LoseCYTK / S&P -14.71% / 5.36% |
LoseCYTK / S&P CYTK unavailable / 2.99% |
| 2019-Q31/3 |
LoseCYTK / S&P 1.16% / 1.70% |
WinCYTK / S&P 40.38% / 5.02% |
LoseCYTK / S&P CYTK unavailable / 0.21% |
| 2019-Q22/3 |
WinCYTK / S&P 39.06% / 4.30% |
WinCYTK / S&P 101.86% / 6.64% |
LoseCYTK / S&P CYTK unavailable / 8.65% |
| 2019-Q12/3 |
WinCYTK / S&P 28.01% / 13.65% |
WinCYTK / S&P 139.57% / 8.12% |
LoseCYTK / S&P CYTK unavailable / 14.29% |
| 2018-Q41/3 |
LoseCYTK / S&P -35.84% / -13.52% |
WinCYTK / S&P 135.64% / 9.05% |
LoseCYTK / S&P CYTK unavailable / 18.23% |
| 2018-Q31/3 |
WinCYTK / S&P 18.67% / 7.71% |
LoseCYTK / S&P -52.48% / 10.21% |
LoseCYTK / S&P CYTK unavailable / 19.06% |
| 2018-Q21/3 |
WinCYTK / S&P 15.28% / 3.43% |
LoseCYTK / S&P -82.25% / 9.03% |
LoseCYTK / S&P CYTK unavailable / 14.46% |
| 2018-Q10/3 |
LoseCYTK / S&P -11.66% / -0.76% |
LoseCYTK / S&P -85.82% / 7.68% |
LoseCYTK / S&P CYTK unavailable / 12.46% |
| 2017-Q40/3 |
LoseCYTK / S&P -43.79% / 6.64% |
LoseCYTK / S&P -87.44% / 7.03% |
LoseCYTK / S&P CYTK unavailable / 13.82% |
| 2017-Q31/3 |
WinCYTK / S&P 19.83% / 4.48% |
LoseCYTK / S&P -43.97% / 5.68% |
LoseCYTK / S&P CYTK unavailable / 17.57% |
| 2017-Q21/3 |
LoseCYTK / S&P -5.84% / 3.09% |
WinCYTK / S&P 211.33% / 4.83% |
LoseCYTK / S&P CYTK unavailable / 17.74% |
| 2017-Q11/3 |
LoseCYTK / S&P 5.76% / 6.07% |
WinCYTK / S&P 212.69% / 3.67% |
LoseCYTK / S&P CYTK unavailable / 13.32% |
| 2016-Q42/3 |
WinCYTK / S&P 32.35% / 3.82% |
WinCYTK / S&P 271.30% / 2.09% |
LoseCYTK / S&P CYTK unavailable / 7.05% |
| 2016-Q31/3 |
LoseCYTK / S&P -3.27% / 3.85% |
WinCYTK / S&P 104.20% / 0.20% |
LoseCYTK / S&P CYTK unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | CYTK total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 120.49% | 20.78% |
| Annualized return | 120.49% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | CYTK total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 135.92% | 83.14% |
| Annualized return | 18.73% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | CYTK total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 641.90% | 319.30% |
| Annualized return | 22.19% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |